Sabra Healthcare REIT (NASDAQ:SBRA) Price Target Cut to $21.00 by Analysts at UBS Group

Sabra Healthcare REIT (NASDAQ:SBRA) had its target price decreased by equities research analysts at UBS Group from $22.00 to $21.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the real estate investment trust’s stock. UBS Group’s price target would suggest a potential upside of 4.63% from the company’s current price.

Other research analysts have also recently issued reports about the company. Barclays began coverage on Sabra Healthcare REIT in a report on Tuesday. They set an “overweight” rating and a $21.00 target price on the stock. Scotiabank reduced their price objective on Sabra Healthcare REIT from $22.00 to $19.00 and set a “sector perform” rating on the stock in a research report on Thursday, June 18th. Raymond James Financial initiated coverage on Sabra Healthcare REIT in a research note on Wednesday, June 17th. They set an “underperform” rating on the stock. Citigroup downgraded Sabra Healthcare REIT from a “buy” rating to a “neutral” rating and cut their target price for the stock from $24.00 to $19.00 in a research note on Monday, June 22nd. Finally, Cantor Fitzgerald boosted their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Sabra Healthcare REIT presently has a consensus rating of “Hold” and a consensus price target of $21.45.

Sabra Healthcare REIT Price Performance

SBRA traded up $0.01 on Wednesday, hitting $20.07. 1,265,767 shares of the company’s stock were exchanged, compared to its average volume of 2,725,201. Sabra Healthcare REIT has a fifty-two week low of $17.17 and a fifty-two week high of $21.28. The stock has a market cap of $5.06 billion, a price-to-earnings ratio of 31.84, a P/E/G ratio of 1.47 and a beta of 0.65. The firm has a 50-day moving average price of $19.70 and a 200-day moving average price of $19.68. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.96.

Sabra Healthcare REIT (NASDAQ:SBRA) last posted its quarterly earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $211.74 million for the quarter, compared to the consensus estimate of $209.20 million. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The company’s revenue for the quarter was up 20.9% on a year-over-year basis. During the same period last year, the firm posted $0.37 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, equities analysts anticipate that Sabra Healthcare REIT will post 1.5 earnings per share for the current year.

Hedge Funds Weigh In On Sabra Healthcare REIT

A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. increased its stake in Sabra Healthcare REIT by 21.6% during the fourth quarter. Principal Financial Group Inc. now owns 24,953,351 shares of the real estate investment trust’s stock worth $472,617,000 after purchasing an additional 4,431,897 shares during the period. Bank of Montreal Can boosted its stake in shares of Sabra Healthcare REIT by 8.2% in the third quarter. Bank of Montreal Can now owns 2,787,655 shares of the real estate investment trust’s stock valued at $51,962,000 after purchasing an additional 211,686 shares during the period. Legal & General Group Plc boosted its stake in shares of Sabra Healthcare REIT by 16.5% in the fourth quarter. Legal & General Group Plc now owns 1,427,180 shares of the real estate investment trust’s stock valued at $27,031,000 after purchasing an additional 201,667 shares during the period. UBS Group AG grew its holdings in shares of Sabra Healthcare REIT by 143.1% in the fourth quarter. UBS Group AG now owns 1,460,219 shares of the real estate investment trust’s stock valued at $27,657,000 after purchasing an additional 859,584 shares in the last quarter. Finally, Advisors Capital Management LLC increased its stake in Sabra Healthcare REIT by 3.2% during the 4th quarter. Advisors Capital Management LLC now owns 2,382,935 shares of the real estate investment trust’s stock worth $45,133,000 after buying an additional 73,281 shares during the period. Hedge funds and other institutional investors own 99.40% of the company’s stock.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.